Effect of an Antimicrobial Agent on Atherosclerotic Plaques. Assessment of Metalloproteinase Activity by Molecular Imaging

Journal of the American College of Cardiology

Volumn 55, Issue 12, 2010, Pages 1240-1249

  Ohshima, Satoru ^a   Fujimoto, Shinichiro ^a   Petrov, Artiom ^a   Nakagami, Hironori ^b   Haider, Nezam ^a   Zhou, Jun ^a   Tahara, Nobuhiro ^a   Osako, Mariana Kiomy ^b   Fujimoto, Ai ^a   Zhu, Jie ^a   Murohara, Toyoaki ^b   Edwards, D Scott ^c   Narula, Navneet ^a   Wong, Nathan D ^a   Chandrashekhar, Y ^d   Morishita, Ryuichi ^b   Narula, Jagat ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c A Subsidiary of Lantheus Holdings   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

atherosclerosis; molecular imaging; proteinases; tetracyclines

Indexed keywords

ANTIINFECTIVE AGENT; FLUINDOSTATIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; MINOCYCLINE; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL ACTIVATION; CELL CULTURE; CHOLESTEROL DIET; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME SYNTHESIS; EVALUATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RABBIT; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTI-INFECTIVE AGENTS; ATHEROSCLEROSIS; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; METALLOPROTEASES; MINOCYCLINE; RABBITS;

EID: 77949282627     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.11.056     Document Type: Article

References (46)

1. Virmani R., Kolodgie F.D., Burke A.P., Farb A., and Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20 (2000) 1262-1275
2. Virmani R., Burke A.P., Farb A., and Kolodgie F.D. Pathology of the vulnerable plaque. J Am Coll Cardiol 47 (2006) C13-C18
3. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
4. Shah P.K., Falk E., Badimon J.J., et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92 (1995) 1565-1569
5. Sukhova G.K., Schonbeck U., Rabkin E., et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99 (1999) 2503-2509
6. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
7. Pasterkamp G., Schoneveld A.H., Hijnen D.J., et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 150 (2000) 245-253
8. Fujimoto S., Hartung D., Ohshima S., et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol 52 (2008) 1847-1857
9. Gilbertson-Beadling S., Powers E.A., Stamp-Cole M., et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol 36 (1995) 418-424
10. Golub L.M., Ramamurthy N.S., McNamara T.F., Greenwald R.A., and Rifkin B.R. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 2 (1991) 297-321
11. Petrinec D., Liao S., Holmes D.R., Reilly J.M., Parks W.C., and Thompson R.W. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 23 (1996) 336-346
12. Curci J.A., Petrinec D., Liao S., Golub L.M., and Thompson R.W. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 28 (1998) 1082-1093
13. Boyle J.R., McDermott E., Crowther M., Wills A.D., Bell P.R., and Thompson M.M. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J Vasc Surg 27 (1998) 354-361
14. Curci J.A., Mao D., Bohner D.G., et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 31 (2000) 325-342
15. Steinmeyer J., Daufeldt S., and Taiwo Y.O. Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage. Biochem Pharmacol 55 (1998) 93-100
16. Greenwald R.A., Moak S.A., Ramamurthy N.S., and Golub L.M. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 19 (1992) 927-938
17. Greenwald R.A., Golub L.M., Lavietes B., et al. Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol 14 (1987) 28-32
18. Greenwald R.A., Golub L.M., Ramamurthy N.S., Chowdhury M., Moak S.A., and Sorsa T. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone 22 (1998) 33-38
19. Fife R.S., and Sledge Jr. G.W. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med 125 (1995) 407-411
20. Seftor R.E., Seftor E.A., De Larco J.E., et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 16 (1998) 217-225
21. Zhu S., Stavrovskaya I.G., Drozda M., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78
22. Chen M., Ona V.O., Li M., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6 (2000) 797-801
23. Nieman G.F., and Zerler B.R. A role for the anti-inflammatory properties of tetracyclines in the prevention of acute lung injury. Curr Med Chem 8 (2001) 317-325
24. Sapadin A.N., and Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54 (2006) 258-265
25. Kolodgie F.D., Petrov A., Virmani R., et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation 108 (2003) 3134-3139
26. Su H., Spinale F.G., Dobrucki L.W., et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 112 (2005) 3157-3167
27. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
28. Golub L.M., Lee H.M., Ryan M.E., Giannobile W.V., Payne J., and Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12 (1998) 12-26
29. Smith Jr. G.N., Brandt K.D., and Hasty K.A. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum 39 (1996) 235-244
30. Uitto V.J., Firth J.D., Nip L., and Golub L.M. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann N Y Acad Sci 732 (1994) 140-151
31. Hanemaaijer R., Visser H., Koolwijk P., et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 12 (1998) 114-118
32. Bendeck M.P., Conte M., Zhang M., Nili N., Strauss B.H., and Farwell S.M. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 160 (2002) 1089-1095
33. Islam M.M., Franco C.D., Courtman D.W., and Bendeck M.P. A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening. Am J Pathol 163 (2003) 1557-1566
34. Pinney S.P., Chen H.J., Liang D., Wang X., Schwartz A., and Rabbani L.E. Minocycline inhibits smooth muscle cell proliferation, migration and neointima formation after arterial injury. J Cardiovasc Pharmacol 42 (2003) 469-476
35. Brown D.L., Desai K.K., Vakili B.A., Nouneh C., Lee H.M., and Golub L.M. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 24 (2004) 733-738
36. Madan M., Bishayi B., Hoge M., Messas E., and Amar S. Doxycycline affects diet- and bacteria-associated atherosclerosis in an ApoE heterozygote murine model: cytokine profiling implications. Atherosclerosis 190 (2007) 62-72
37. Scarabelli T.M., Stephanou A., Pasini E., et al. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J Am Coll Cardiol 43 (2004) 865-874
38. Haider N., Hartung D., Fujimoto S., et al. Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. J Nucl Cardiol 16 (2009) 753-762
39. Axisa B., Loftus I.M., Naylor A.R., et al. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 33 (2002) 2858-2864
40. Matsuyama A., Sakai N., Ishigami M., Hiraoka H., and Yamashita S. Minocycline for the treatment of Takayasu arteritis. Ann Intern Med 143 (2005) 394-395
41. Prall A.K., Longo G.M., Mayhan W.G., et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg 35 (2002) 923-929
42. Walker C., Thomas J., Nango S., Lennon J., Wetzel J., and Powala C. Long-term treatment with subantimicrobial dose doxycycline exerts no antibacterial effect on the subgingival microflora associated with adult periodontitis. J Periodontol 71 (2000) 1465-1471
43. Boersma H, Wolters SL, Petrov A, et al. Minimization of infarct size with minocycline: imaging with annexin-A5 evaluation. Paper presented at: 8th International Conference of Nuclear Cardiology; May 2, 2007; Prague, Czech Republic.
44. Sarai M., Hartung D., Petrov A., et al. Broad and specific caspase inhibitor-induced acute repression of apoptosis in atherosclerotic lesions evaluated by radiolabeled annexin A5 imaging. J Am Coll Cardiol 50 (2007) 2305-2312
45. Muhlestein J.B., Anderson J.L., Cariquest J.F., et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary Clinical Results of the ACADEMIC study. Circulation 102 (2000) 1755-1760
46. Grayston J.T., Kronmal R.A., Jackson L.A., et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 352 (2005) 1637-1645